List of Excipients in Branded Drug QUADRAMET

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lantheus Medical Imaging Inc	QUADRAMET	samarium sm 153 lexidronam	11994-016	CALCIUM HYDROXIDE
Lantheus Medical Imaging Inc	QUADRAMET	samarium sm 153 lexidronam	11994-016	LEXIDRONAM
Lantheus Medical Imaging Inc	QUADRAMET	samarium sm 153 lexidronam	11994-016	SAMARIUM

Quadramet Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Quadramet is a sterile, single-dose radiopharmaceutical containing samarium Sm-153 lexidronam for palliation of pain from osteoblastic bone metastases. Its excipient strategy is inseparable from its radiochemistry: the ligand system controls samarium binding, biodistribution, in-use stability, and product quality. The most credible commercial opportunities are in licensed radiopharmaceutical manufacturing, isotope supply, hospital distribution, analytical services, and reformulation support rather than conventional excipient substitution.

What is Quadramet and how does its formulation work?

Quadramet contains samarium-153 complexed with lexidronam, also known as EDTMP. The complex targets areas of increased bone turnover, where the phosphonate ligand localizes the radioisotope. Samarium-153 emits beta radiation for therapeutic effect and gamma radiation that permits imaging and distribution assessment.

Attribute	Quadramet
Active ingredient	Samarium Sm-153 lexidronam
Ligand	Ethylenediaminetetramethylene phosphonate, commonly abbreviated EDTMP
Dosage form	Sterile injectable radiopharmaceutical
Route	Intravenous
Therapeutic use	Relief of pain from osteoblastic metastatic bone lesions
Product type	Small-molecule radiopharmaceutical
FDA approval	NDA 20-981; approved in 1997
Administration setting	Nuclear medicine and hospital radiopharmacy
Biosimilar pathway	Not applicable
Principal technical risks	Isotope availability, radiochemical purity, sterility, stability, radiation handling, and distribution

The product is administered as a single dose calculated by patient body weight. The radioactivity decays rapidly, creating a commercial model based on production scheduling, calibration, delivery time, and hospital use rather than conventional multi-month inventory.

What excipients are used in Quadramet?

Quadramet's formulation uses a phosphonate ligand and associated inorganic components to produce a stable samarium complex in aqueous solution. The approved labeling identifies the product as a solution containing samarium Sm-153 lexidronam with formulation components that include EDTMP-related phosphonate chemistry and calcium-based constituents. The product is supplied as a sterile, single-use injectable solution rather than a preserved multidose product. [1]

The most important formulation elements are:

1. The lexidronam ligand, which coordinates samarium-153 and drives skeletal localization.
2. Calcium and related buffer or complexation components, which support formulation chemistry and manufacturing control.
3. Sodium and phosphate-related ionic components associated with the injectable formulation.
4. Water for injection as the liquid vehicle.
5. A sterile single-dose container system compatible with radioactive materials.

The ligand is commercially more important than a conventional inactive ingredient. A change to EDTMP concentration, metal-to-ligand ratio, pH, ionic strength, or calcium content can affect:

• Radiochemical purity
• Free samarium formation
• Bone-to-soft-tissue distribution
• Urinary excretion
• Injectability
• Shelf life and activity at calibration
• Radiation exposure to non-target tissues
• Release testing specifications

For that reason, a Quadramet competitor cannot treat the excipient package as a simple substitution opportunity. The ligand and metal-complexation system form part of the product's functional identity.

How does Quadramet's excipient strategy compare with conventional injectable drugs?

Quadramet differs from conventional injectables in three commercially important ways.

The ligand is a performance-critical excipient

In a conventional drug, an excipient may primarily control pH, osmolality, viscosity, or preservation. In Quadramet, the phosphonate ligand participates directly in active drug formation. It determines whether samarium remains in the intended chelated form and whether the complex localizes appropriately in bone.

The formulation must be stable during radioactive decay

The product does not remain chemically static. Samarium-153 has a physical half-life of approximately 46.3 hours. Radiation can promote radiolysis, alter the ligand environment, and generate degradants. Formulation development therefore requires radiochemical stability testing under actual activity conditions, not only conventional chemical stability studies.

The supply chain is time-sensitive

A formulation manufactured at a central facility must reach the hospital while the product remains within its release and clinical-use specifications. Commercial value therefore resides in integrated isotope production, formulation, quality control, packaging, and delivery.

What formulation patents protect Quadramet?

The relevant intellectual-property estate historically centered on the samarium-153 phosphonate complex, radiolabeled EDTMP chemistry, manufacturing methods, and therapeutic use. Core composition and method patents associated with a product approved in 1997 would generally be expected to have reached the end of their ordinary U.S. patent terms, subject to patent-specific filing dates, patent-term adjustment, patent-term extension, and jurisdiction.

Publicly available FDA materials identify Quadramet's approved active ingredient and NDA history but do not establish an active, commercially blocking U.S. patent estate for the legacy product. [2] A current freedom-to-operate analysis would need to distinguish:

• Expired composition-of-matter claims
• Expired manufacturing claims
• Use claims covering pain palliation
• Later patents on chelation chemistry
• Patents covering alternative radionuclides or delivery systems
• Know-how that is not disclosed in patent claims

The practical barrier is more likely to be regulatory and operational than a live foundational patent monopoly.

When does Quadramet lose exclusivity?

Quadramet's original regulatory exclusivity and core patent protection are historical rather than current market barriers. The product was approved in 1997, and any five-year new chemical entity exclusivity would have expired long ago. The principal commercial question is therefore not the expiration of original exclusivity but whether a new entrant can reproduce the product's quality attributes and establish a reliable isotope supply chain.

For a competing product, potential regulatory routes include:

• An abbreviated application if the product can meet applicable sameness requirements
• A 505(b)(2) application for a materially different formulation, manufacturing process, or clinical use
• A full application if comparative data cannot support an abbreviated route
• A hospital-use or compounding model where legally permitted, although radiopharmaceutical compounding is subject to specific federal and state requirements

The regulatory pathway depends on the proposed product's active ingredient definition, dosage form, radionuclide specification, manufacturing process, labeling, and evidence of therapeutic equivalence. [3]

What commercial opportunities exist in Quadramet excipients?

1. Qualified phosphonate ligand supply

The highest-value excipient opportunity is supply of pharmaceutical-grade EDTMP or an equivalent qualified phosphonate ligand. Suppliers can differentiate through:

• Low trace-metal content
• Consistent phosphorus assay
• Control of regioisomeric or process-related impurities
• Lot-to-lot complexation performance
• Documentation for radiopharmaceutical manufacturing
• Short lead times and dual-source qualification

A ligand supplier that can support validated samarium complexation and provide robust analytical documentation may capture more value than a commodity excipient vendor.

2. Custom formulation and radiolabeling services

Contract development and manufacturing organizations can offer:

• Cold-kit development
• Samarium complexation process development
• Radiochemical purity testing
• Sterility and endotoxin testing
• Stability studies under radioactive conditions
• Aseptic filling into shielded containers
• Release testing at activity-specific time points

These services are valuable because radiopharmaceutical manufacturers need specialized facilities, radiation controls, validated analytical methods, and trained personnel.

3. Isotope and ligand supply integration

A vertically integrated supplier can combine:

• Samarium-152 or enriched precursor supply
• Neutron activation or other isotope-production capability
• EDTMP ligand manufacture
• Radiolabeling
• Dose calibration
• Regional distribution

This model reduces dependence on separate isotope, excipient, and fill-finish vendors. It also allows production planning around reactor schedules and hospital demand.

4. Alternative container and delivery systems

Commercial opportunities exist in containers designed for radioactive injectables, including:

• Low-extractables glass vials
• Radiation-compatible elastomer closures
• Shielded secondary packaging
• Dose-calibrated syringes
• Automated dispensing systems
• Improved transport systems for short half-life products

Packaging changes may not create a new drug product by themselves, but they can reduce operator exposure, improve dose accuracy, and lower product loss during distribution.

5. Hospital radiopharmacy workflow products

Hospitals may value systems that reduce preparation and administration time. Opportunities include:

• Dose-management software
• Barcode-based isotope tracking
• Activity decay calculators
• Automated syringe preparation
• Radiochemical quality-control instruments
• Waste-minimization systems
• Scheduling platforms linked to patient arrival and isotope delivery

These products address the operational constraints created by samarium-153 decay.

What manufacturing and intellectual-property barriers affect Quadramet competition?

The main manufacturing barrier is controlled radiolabeling under time and activity constraints. A new entrant must demonstrate that the product is chemically and radiochemically consistent across the manufacturing window.

Key quality attributes include:

Quality attribute	Commercial relevance
Radiochemical purity	Limits free samarium and non-target distribution
Chemical purity	Controls ligand and process impurities
Radionuclidic purity	Confirms isotope identity and limits unwanted radiation
Specific activity	Affects dose composition and complexation behavior
Sterility	Required for intravenous administration
Endotoxin level	Controls pyrogenic risk
pH and osmolality	Affects injectability and tolerability
Container closure integrity	Prevents contamination and radioactive leakage
Stability through expiry	Determines usable distribution window

The intellectual-property risk is more likely to arise from later improvements than from the original Quadramet concept. Potentially relevant claims could cover:

• New phosphonate ligands
• Alternative bone-targeting complexes
• Improved radiochemical stability
• Specific impurity limits
• Automated manufacturing methods
• Combination treatment with systemic anticancer agents
• Imaging-assisted dose selection
• New radionuclides using related chelation chemistry

Trade secrets may also matter. These can include ligand purification methods, metal-ion control, isotope loading conditions, pH adjustment, filtration sequence, and time-dependent release procedures.

What is the FDA regulatory status of Quadramet?

Quadramet was approved by the FDA under NDA 20-981 for palliation of pain associated with osteoblastic metastatic bone disease. The product is a therapeutic radiopharmaceutical, not a biologic, and therefore has no biosimilar exposure under the Public Health Service Act. [1, 2]

The commercial status of the legacy product should be checked against the FDA's current Drugs@FDA records and the sponsor's distribution status. FDA approval does not guarantee continuous commercial availability. Radiopharmaceuticals can leave the market because of isotope shortages, manufacturing economics, facility changes, or low hospital utilization even when the NDA remains in the regulatory record.

What is the Orange Book status of Quadramet?

The Orange Book is relevant because Quadramet was approved as a drug under an NDA. An Orange Book review should address:

• Whether the NDA is listed as active or discontinued
• Whether any patents were listed for the product
• Whether listed patents remain unexpired
• Whether an applicant could certify under Paragraph IV
• Whether the proposed product would rely on an abbreviated application or a 505(b)(2) application

A Paragraph IV challenge is commercially meaningful only if an unexpired listed patent remains relevant to the proposed product. For a legacy radiopharmaceutical approved in 1997, the more likely risk is regulatory comparability and isotope supply rather than an active Orange Book patent blocking entry. [2, 4]

Which companies are challenging Quadramet?

No current, prominent Paragraph IV challenger is established in the core public FDA materials cited here. Competitive pressure is more likely to come from alternative bone-seeking radiopharmaceuticals than from a direct generic copy.

Relevant competitive products and technologies include:

• Strontium-89 chloride
• Rhenium-186 etidronate
• Radium-223 dichloride
• Lutetium-177 radioligand therapies
• Other alpha- and beta-emitting bone-targeted agents

These products do not necessarily compete on formulation sameness. They compete on survival impact, pain control, safety, treatment setting, physician familiarity, isotope supply, and reimbursement.

How does Quadramet compare with competing bone-targeted radiopharmaceuticals?

Product or technology	Primary target or use	Formulation opportunity	Competitive distinction
Quadramet	Osteoblastic bone lesions	Samarium-153 phosphonate complex	Established bone localization and pain palliation
Strontium-89	Osteoblastic bone pain	Simple radiometal salt	Longer physical half-life and different radiation profile
Radium-223	Bone metastases in specified prostate cancer settings	Calcium-mimetic radiopharmaceutical	Disease-specific clinical and survival positioning
Lutetium-177 agents	Molecular targets such as PSMA or somatostatin receptors	Chelator-based radioligands	Targeted systemic oncology applications
Rhenium-186 agents	Bone pain and related applications	Metal-phosphonate complexes	Alternative isotope and radiation characteristics

Quadramet's excipient strategy is strongest where the ligand system provides reliable bone targeting and manufacturing reproducibility. Its commercial weakness is the narrow palliative indication and dependence on short-lived isotope logistics.

What generic launch risks exist for Quadramet?

A direct generic or follow-on launch would face five principal risks:

1. Demonstrating equivalent radiochemical purity and biodistribution.
2. Securing a dependable samarium-153 supply.
3. Building licensed manufacturing and radioactive-material handling capacity.
4. Distributing doses within the usable activity window.
5. Generating sufficient hospital demand to support production economics.

A low-cost excipient alone is unlikely to create a defensible product. The commercial package must include qualified ligand supply, isotope access, validated manufacturing, radiopharmacy distribution, and regulatory documentation.

What licensing deals could create value around Quadramet technology?

The most practical licensing structures would involve:

• Exclusive regional rights to a samarium-153 product
• Supply agreements for pharmaceutical-grade EDTMP
• Contract radiolabeling and fill-finish
• Technology transfer for cold-kit or centralized manufacturing
• Hospital distribution partnerships
• Licensing of automated radiopharmacy systems
• Co-development of next-generation phosphonate radiopharmaceuticals

A license focused only on legacy Quadramet composition claims would have limited value if core patent terms have expired. A license that combines manufacturing know-how, isotope access, regulatory files, and hospital distribution could retain commercial relevance.

Key Takeaways

• Quadramet is samarium Sm-153 lexidronam, a bone-seeking therapeutic radiopharmaceutical.
• Its excipient strategy is functional: the EDTMP ligand controls samarium complexation and skeletal localization.
• The product is a sterile, single-dose injectable with a time-sensitive radioactive supply chain.
• Original FDA exclusivity and likely core patent protection are historical, not current primary barriers.
• The strongest commercial opportunities are qualified ligand supply, radiolabeling, contract manufacturing, isotope integration, packaging, and radiopharmacy workflow systems.
• No biosimilar pathway applies.
• Direct generic entry would be constrained more by radiochemical equivalence, isotope supply, and distribution than by conventional excipient cost.
• Competitive threats come mainly from alternative radiopharmaceuticals, including radium-223 and lutetium-177 products.

FAQs

Is EDTMP an active ingredient or an excipient in Quadramet?

EDTMP is the ligand component of the samarium-153 lexidronam complex. It is not a conventional inactive excipient because it participates directly in formation and targeting of the radiopharmaceutical complex.

Can Quadramet be reformulated with a different chelator?

A different chelator would likely create a new radiopharmaceutical with different chemistry, biodistribution, stability, and regulatory requirements. It would not be a routine excipient substitution.

Does Quadramet have biosimilar competition?

No. Quadramet is a radiolabeled small-molecule drug, not a biological product. Competitive products would follow drug and radiopharmaceutical pathways rather than biosimilar pathways.

What is the most valuable supply-chain component for a Quadramet follow-on?

Reliable samarium-153 supply combined with pharmaceutical-grade ligand and validated radiolabeling capacity is more valuable than commodity excipient sourcing alone.

Could a hospital compound a Quadramet substitute?

A hospital cannot assume that compounding a samarium-153 phosphonate solution creates an equivalent commercial product. Radiopharmaceutical preparation is subject to applicable FDA, state, nuclear-material, pharmacy, sterility, and quality-control requirements.

References

1. U.S. Food and Drug Administration. (1997). Quadramet (samarium Sm-153 lexidronam injection) prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Quadramet, NDA 20-981.
3. U.S. Food and Drug Administration. (2018). Development of radiopharmaceuticals for use in clinical trials and/or as commercially marketed drug products: Guidance for industry.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
5. International Atomic Energy Agency. (n.d.). Radiopharmaceutical production and quality control guidance for therapeutic radionuclides.